Page last updated: 2024-11-07

sepimostate mesilate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sepimostate mesilate: used in therapy of pancreatitis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108040
CHEMBL ID1201881
SCHEMBL ID15536391
MeSH IDM0354561

Synonyms (19)

Synonym
sepimostat mesylate
CHEMBL1201881
sepimostat mesilate
fut-187
sepimostate mesilate
6-(aminoiminomethyl)-2-naphthalenyl 4-((4,5-dihydro-1h-imidazol-2-yl)aminobenzoate dimethanesulfonate
6-amidino-2-naphthyl 4-((4,5-dihydro-1h-imidazol-2-yl)amino)benzoate dimethanesulfonate
benzoic acid, 4-((4,5-dihydro-1h-imidazol-2-yl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dimethanesulfonate
fut 187
6-amidino-2-naphthyl-(4-(4,5-dihydro-1h-imidazol-2-yl)amino)benzoate dimethanesulfonate
unii-8mw790bpkq
103926-82-5
8mw790bpkq ,
benzoic acid, 4-[(4,5-dihydro-1h-imidazol-2-yl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester, methanesulfonate (1:2)
SCHEMBL15536391
Q27270767
(6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydro-1h-imidazol-2-ylamino)benzoate;methanesulfonic acid
DTXSID50908668
methanesulfonic acid--6-carbamimidoylnaphthalen-2-yl 4-[(4,5-dihydro-1h-imidazol-2-yl)amino]benzoate (1/1)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 1) LD50 values in mice were 4,395 mg/kg for males and 3,626 mg/kg for females orally, 6,284 mg/kg for males and 5,492 mg/kg for females subcutaneously, and 39."( [Acute toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethanesulfonate (FUT-187) in mice, rats and dogs.
Kuramoto, S; Otani, K; Shimamura, K; Terabayashi, M; Terazawa, K; Watanabe, K; Yamashita, K; Yokomoto, Y, 1992
)
0.28
" The results are summarized as follows: There were no deaths or toxic signs caused by the drug throughout the experimental period."( [A 52-week oral chronic toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) in rats with a recovery period of 5 weeks.
Aikawa, T; Hatayama, K; Maruden, A; Okazaki, S; Tamura, K; Terazawa, K; Yamazaki, E, 1992
)
0.28
" In addition, one male given 30 mg/kg/day was euthanatized due to extreme weakness, as weight loss and pallid oral mucosa, and another male in the same group died after showing acute toxic symptoms such as hyperpnea, tonic convulsion and ataxic gait."( [A 52-week chronic oral toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) in dogs].
Asanoma, H; Hirota, T; Irimura, K; Nakano, S; Terazawa, K; Yada, H, 1992
)
0.28
" There were no adverse effects on delivery and lactation and no significant changes on neonatal development, growth, reproduction and learning ability in the F1 offspring."( [Reproductive and developmental toxicity studies of FUT-187. (III)--Postnatal study in rat F1 offspring from dams treated orally with FUT-187 during the period of fetal organogenesis].
Igarashi, Y; Imai, S; Kawanishi, H; Maruden, A; Shimamura, K; Shiraishi, M; Takeshima, T; Toyohara, S, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" 4) On autopsy, changes attributable to local irritation by FUT-187 were seen in all species except mice and rats dosed intravenously."( [Acute toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethanesulfonate (FUT-187) in mice, rats and dogs.
Kuramoto, S; Otani, K; Shimamura, K; Terabayashi, M; Terazawa, K; Watanabe, K; Yamashita, K; Yokomoto, Y, 1992
)
0.28
"To assess the subacute toxicity of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) a 13 week subacute toxicity study by gavage was done in Cynomolgus monkeys at dosage levels of 0, 15, 45 and 135 mg/kg/day."( The evaluation of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) by oral administration in cynomolgus monkeys in a 13 week subacute toxicity study.
Maruden, A; Spicer, EJ; Terazawa, K, 1992
)
0.28
" FUT-187 was dosed by gavage at 0, 50, 200 and 800 mg/kg/day from day 7 to 17 of gestation."( [Reproductive and developmental toxicity studies of FUT-187. (III)--Postnatal study in rat F1 offspring from dams treated orally with FUT-187 during the period of fetal organogenesis].
Igarashi, Y; Imai, S; Kawanishi, H; Maruden, A; Shimamura, K; Shiraishi, M; Takeshima, T; Toyohara, S, 1992
)
0.28
" In dams, an increased pancreas weight in the 20 mg/kg or more groups, temporary salivation after dosing in the 120 mg/kg or more groups, and a depression of body weight gain and decreased food intake and weight of the carcass in the 720 mg/kg group were statistically significant in comparison with controls."( [Reproductive and developmental toxicity studies of FUT-187. (V)--Perinatal and postnatal study in rats with oral administration of FUT-187].
Furuhashi, T; Kurihara, H; Maruden, A; Shimamura, K; Takei, A; Uehara, M; Yoshida, R, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Complement C1r subcomponentHomo sapiens (human)Ki6.40006.40006.40006.4000AID72361
Coagulation factor XHomo sapiens (human)Ki20.40000.00000.47089.0000AID51844
Kallikrein-1Homo sapiens (human)Ki0.61000.06100.41570.6100AID155098
Trypsin-1Homo sapiens (human)Ki0.29000.00001.76768.9000AID215749
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
immune responseComplement C1r subcomponentHomo sapiens (human)
complement activation, classical pathwayComplement C1r subcomponentHomo sapiens (human)
zymogen activationComplement C1r subcomponentHomo sapiens (human)
innate immune responseComplement C1r subcomponentHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
zymogen activationKallikrein-1Homo sapiens (human)
regulation of systemic arterial blood pressureKallikrein-1Homo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityComplement C1r subcomponentHomo sapiens (human)
calcium ion bindingComplement C1r subcomponentHomo sapiens (human)
protein bindingComplement C1r subcomponentHomo sapiens (human)
serine-type peptidase activityComplement C1r subcomponentHomo sapiens (human)
identical protein bindingComplement C1r subcomponentHomo sapiens (human)
molecular sequestering activityComplement C1r subcomponentHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
serine-type endopeptidase activityKallikrein-1Homo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionComplement C1r subcomponentHomo sapiens (human)
extracellular spaceComplement C1r subcomponentHomo sapiens (human)
extracellular exosomeComplement C1r subcomponentHomo sapiens (human)
blood microparticleComplement C1r subcomponentHomo sapiens (human)
extracellular spaceComplement C1r subcomponentHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
nucleusKallikrein-1Homo sapiens (human)
extracellular exosomeKallikrein-1Homo sapiens (human)
secretory granuleKallikrein-1Homo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID72361Binding affinity against factor C1r.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID51844Binding affinity against Coagulation factor X2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID226854Inhibitory activity against complement mediated hemoyses in alternate pathway.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID155098Binding affinity against pancreatic kallikrein.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID160003Binding affinity against plasma kallikrein.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID215749Binding affinity against trypsin.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID157650Binding affinity against plasma thrombin2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID226855Inhibitory activity against complement mediated hemoyses in classical pathway.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.70)18.7374
1990's23 (85.19)18.2507
2000's2 (7.41)29.6817
2010's1 (3.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index6.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (14.81%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (81.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]